| Literature DB >> 22292497 |
Michael P Weekes1, Robin Antrobus, Suzanne Talbot, Simon Hör, Nikol Simecek, Duncan L Smith, Stuart Bloor, Felix Randow, Paul J Lehner.
Abstract
The endoplasmic reticulum chaperone gp96 is required for the cell surface expression of a narrow range of proteins, including toll-like receptors (TLRs) and integrins. To identify a more comprehensive repertoire of proteins whose cell surface expression is dependent on gp96, we developed plasma membrane profiling (PMP), a technique that combines SILAC labeling with selective cell surface aminooxy-biotinylation. This approach allowed us to compare the relative abundance of plasma membrane (PM) proteins on gp96-deficient versus gp96-reconstituted murine pre-B cells. Analysis of unfractionated tryptic peptides initially identified 113 PM proteins, which extended to 706 PM proteins using peptide prefractionation. We confirmed a requirement for gp96 in the cell surface expression of certain TLRs and integrins and found a marked decrease in cell surface expression of four members of the extended LDL receptor family (LDLR, LRP6, Sorl1 and LRP8) in the absence of gp96. Other novel gp96 client proteins included CD180/Ly86, important in the B-cell response to lipopolysaccharide. We highlight common structural motifs in these client proteins that may be recognized by gp96, including the beta-propeller and leucine-rich repeat. This study therefore identifies the extended LDL receptor family as an important new family of proteins whose cell surface expression is regulated by gp96.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22292497 PMCID: PMC3292266 DOI: 10.1021/pr201135e
Source DB: PubMed Journal: J Proteome Res ISSN: 1535-3893 Impact factor: 5.370
Figure 1Plasma membrane profiling workflow. Heavy and light labeled cells are mixed early in the procedure and sialylated glycoproteins oxidized and biotinylated. The enriched glycoproteins are digested and bound N-linked glycopeptides are released using PNGase F. Eluates are prepared for LC–MS/MS.
Proteins Enriched using PMP were Identified by LC–MS/MS and their Subcellular Location Inferred from GOCC Termsa
| unfractionated | all fractions Mascot | all fractions Andromeda | all fractions combined | |
|---|---|---|---|---|
| Total proteins identified | 135 | 1709 | 1551 | 1826 |
| Total proteins quantified | 93 | 1181 | 1137 | 1271 |
| Membrane | 127 | 1352 | 1241 | 1433 |
| Plasma membrane or Cell surface (PM/CS) | 91 | 481 | 452 | 509 |
| Extracellular but not PM/CS (XC) | 3 | 48 | 39 | 54 |
| Short GO description (ShG) | 19 | 141 | 129 | 143 |
| Nuclear but not PM/CS/XC/ShG | 3 | 352 | 318 | 377 |
| Total PM/CS/XC | 94 | 529 | 491 | 563 |
| Total PM/CS/XC/ShG | ||||
| % PM/CS/XC of all identified + annotated proteins | 70% | 34% | 35% | 35% |
| % PM/CS/XC/ShG of all identified+annotated proteins |
Numbers of proteins are shown with the indicated annotations. The percent PM/CS/XC is calculated as (PM/CS/XC annotations/(total protein identifications – proteins without GOCC annotation)).
Figure 2Scatterplot of all proteins identified by ≥2 peptides. Fold change (x-axis) is shown as log2, and summed ion intensity (y-axis) is shown as log10. Significance A values were calculated using Perseus version 1.1.1.13.
Proteins Identified by ≥2 Peptides and Down- or Up-regulated >3 Fold in gp96 Deficient Cellsa
| ratio | peptides | % coverage | significance
A | GOCC | structure | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IPI number | protein name | Mct | Adr | Mct | Adr | Mct | Adr | Mct | Adr | M | P | C | X | N | S | βP | Lrr | Egf | Ig |
| Integrin alpha-4 | 113.2 | 49.2 | 12 | 10 | 13.7 | 11.5 | 9.2 × 10–21 | 6.1 × 10–12 | M | P | C | βP | |||||||
| Integrin alpha L | 73.3 | 43.3 | 27 | 25 | 28.4 | 26 | 2.0 × 10–17 | 2.9 × 10–11 | M | P | βP | ||||||||
| Low-density lipoprotein receptor-related protein 6 | 65.6 | 21.9 | 12 | 10 | 9.2 | 7.6 | 1.3 × 10–16 | 5.2 × 10–8 | M | P | βP | Egf | |||||||
| Integrin alpha 9 | 63.5 | 37.8 | 10 | 10 | 11.8 | 12 | 2.1 × 10–16 | 1.4 × 10–10 | M | P | βP | ||||||||
| CD180 antigen | 52.5 | 22.4 | 9 | 8 | 19.2 | 16.8 | 4.3 × 10–15 | 4.2 × 10–8 | M | P | Lrr | ||||||||
| Low-density lipoprotein receptor | 35.0 | 25.2 | 22 | 16 | 27.8 | 22.5 | 1.7 × 10–12 | 1.3 × 10–8 | M | P | X | βP | Egf | ||||||
| Desmoplakin | 32.7 | 9.9 | 9 | 5 | 3.2 | 2 | 4.4 × 10–12 | 5.4 × 10–5 | M | P | |||||||||
| Sortilin-related receptor | 32.3 | 29.5 | 9 | 8 | 5.5 | 4.9 | 5.2 × 10–12 | 2.4 × 10–9 | M | X | βP | Egf | |||||||
| Integrin beta-2 | 26.3 | 25.1 | 23 | 21 | 37.5 | 35.5 | 7.9 × 10–11 | 1.3 × 10–8 | M | P | C | Egf | |||||||
| Latrophilin-1 | 24.6 | 24.0 | 2 | 3 | 1.6 | 2.4 | 1.9 × 10–10 | 2.0 × 10–8 | M | P | |||||||||
| Junction plakoglobin | 21.8 | 17.2 | 9 | 8 | 14.1 | 12.6 | 8.2 × 10–10 | 5.4 × 10–7 | M | P | N | ||||||||
| Fibronectin | 19.6 | 39.8 | 5 | 2 | 2.4 | 1.1 | 3.0 × 10–9 | 8.0 × 10–11 | M | P | X | ||||||||
| Lymphocyte antigen 86 | 18.2 | 2 | 1 | 16.7 | 11.1 | 7.1 × 10–9 | X | Ig | |||||||||||
| Integrin alpha V | 17.3 | 17.1 | 28 | 27 | 33.6 | 32.3 | 1.3 × 10–8 | 5.6 × 10–7 | M | P | βP | ||||||||
| Integrin beta-3 | 16.8 | 15.8 | 20 | 18 | 32.7 | 28.2 | 1.7 × 10–8 | 1.1 × 10–6 | M | P | Egf | ||||||||
| Annexin A2 | 13.1 | 9.7 | 3 | 3 | 11.5 | 11.5 | 2.4 × 10–7 | 6.4 × 10–5 | M | P | X | ||||||||
| Leucine-rich repeat-containing protein 4C | 11.0 | 15.1 | 2 | 3 | 3.8 | 5.3 | 1.4 × 10–6 | 1.7 × 10–6 | M | P | Lrr | Ig | |||||||
| Vinculin | 11.0 | 13.0 | 4 | 2 | 4.5 | 2.4 | 1.5 × 10–6 | 6.4 × 10–6 | M | P | |||||||||
| Extracellular LRR and Fn type-III domain protein 1 | 10.3 | 10.1 | 5 | 4 | 8.2 | 7 | 2.6 × 10–6 | 4.5 × 10–5 | M | S | Lrr | ||||||||
| Attractin | 8.3 | 8.2 | 4 | 5 | 4 | 4.9 | 1.9 × 10–5 | 0.0002 | M | P | βP | Egf | |||||||
| N-glycan processing alpha-mannosidase IIx | 7.1 | 6.6 | 2 | 3 | 2.3 | 3.1 | 6.6 × 10–5 | 0.0009 | Egf | ||||||||||
| EGF-containing fibulin-like extracellular matrix protein 1 | 6.5 | 2 | 4.7 | 0.0001 | X | Egf | |||||||||||||
| Adhesion molecule with Ig like domain 1 | 5.8 | 12.5 | 3 | 2 | 5 | 3.2 | 0.0003 | 8.5 × 10–6 | M | S | Lrr | Ig | |||||||
| Low-density lipoprotein receptor-related protein 8 | 5.4 | 2 | 2 | 2.2 | 2.2 | 0.0031 | M | P | X | βP | Egf | ||||||||
| Toll-like receptor 6 | 4.5 | 33.1 | 4 | 3 | 5.2 | 4.8 | 0.0019 | 6.6 × 10–10 | M | P | Lrr | ||||||||
| E1A-binding protein p400 | 4.4 | 1 | 2 | 0.7 | 1.1 | 0.0096 | M | N | |||||||||||
| Endoplasmin | 3.8 | 5.3 | 6 | 5 | 8.9 | 7.7 | 0.0047 | 0.0035 | M | P | |||||||||
| Leucine-rich repeats and Ig-like domains protein 2 | 3.8 | 2 | 1 | 2.5 | 1.4 | 0.0052 | M | P | Lrr | Ig | |||||||||
| Nuclear pore membrane glycoprotein 210 | 3.4 | 3.3 | 13 | 10 | 8 | 6.5 | 0.0092 | 0.0364 | M | N | |||||||||
| Tumor necrosis factor receptor superfamily member 19 | 0.3 | 0.2 | 4 | 3 | 13.2 | 10.8 | 1.8 × 10–16 | 1.9 × 10–15 | M | P | X | ||||||||
| Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase | 0.2 | 2 | 1 | 8 | 3.4 | 4.8 × 10–18 | M | ||||||||||||
| Rapamycin-insensitive companion of mTOR | 0.1 | 1 | 2 | 1 | 2 | 4.1 × 10–30 | |||||||||||||
Ratio is shown as the fold downregulation, calculated by Mascot (Mct) or Andromeda (Adr). Peptides refers to total unique or razor peptides. Significance A values were calculated by MaxQuant or Perseus. For a given protein, GOCC annotations are shown: M (membrane), P (plasma membrane), C (cell surface), X (extracellular), N (nucleus) and S (short GO term). Structural features were determined by literature search and Interpro release 34.0: beta-propeller (βP), leucine rich repeat (Lrr), EGF or EGF-like domain (Egf), immunoglobulin or immunoglobulin-like domain (Ig). Other abbreviations: Fibronectin (Fn). We performed this experiment as a single replicate. Confirmation by flow cytometry used at least three biological replicates (Figure 3).
Figure 3Flow cytometry confirms that LDLR is gp96 dependent. (a) M36 and M36/gp96+ cells or (b) the independent gp96 knockout E4.126 and control GTPT3 cells were stained with monoclonal antibodies against the indicated cell surface targets. At least three replicate stains were performed for each cell surface target, confirming the above observations (data not shown).
Figure 4Fold enrichment of structures over-represented (p < 0.001) in proteins downregulated in the absence of gp96 (Table 2), in comparison to all proteins identified by ≥2 peptides.